MedTrace Logo

NeoVas Bioresorbable Coronary Scaffold Registry Study

NCT02305472 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 825

Last updated 2017-03-09

No results posted yet for this study

Summary

The NeoVas Bioresorbable Coronary Scaffold Registry Trial is a prospective, multi-center, single arm registry trial based on the NeoVas FIM study which verified the safety and effectiveness of NeoVas initially. This study is to evaluate the safety and effectiveness of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion.

Conditions

Interventions

DEVICE

NeoVas BCS

Subjects receiving NeoVas BCS

Sponsors & Collaborators

  • Lepu Medical Technology (Beijing) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yaling Han, MD · The general hospital of Shenyang military region

  • Guosheng Fu · Sir Run Run Shaw Hospital

  • Bo Xu · Beijing Fuwai hospital, National center for cardiovascular diseases China

  • Yao-Jun Zhang · Nanjing First Hospital, Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02305472 on ClinicalTrials.gov